Valuation: BioRestorative Therapies, Inc.

Market Cap 5.12M 4.43M 4.14M 3.79M 7.14M 488M 7.25M 48.59M 19.07M 244M 19.23M 18.81M 814M P/E 2026 *
-0.41x
P/E 2027 * -0.5x
Enterprise Value 5.12M 4.43M 4.14M 3.79M 7.14M 488M 7.25M 48.59M 19.07M 244M 19.23M 18.81M 814M EV / Sales 2026 *
3.64x
EV / Sales 2027 * 2.21x
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day-1.47%
1 week+1.57%
Current month-1.81%
1 month-41.74%
3 months-2.33%
6 months-68.53%
Current year-82.89%
1 week 0.2
Extreme 0.201
0.23
1 month 0.19
Extreme 0.19295
0.37
Current year 0.16
Extreme 0.1593
1.28
1 year 0.16
Extreme 0.1593
1.89
3 years 0.16
Extreme 0.1593
3.67
5 years 0.16
Extreme 0.1593
26.8
10 years 0.16
Extreme 0.1593
20,040
Manager TitleAgeSince
Chief Executive Officer 32 2026-07-12
Investor Relations Contact - -
Corporate Officer/Principal - 2025-10-21
Director TitleAgeSince
Director/Board Member 28 2026-06-11
Director/Board Member 37 2026-06-11
Director/Board Member - 2026-07-12
Date Insider Type Main position Quantity % Market Cap.
10/6/25 Free

Chief Technology Officer

23,438 0.2938%
10/6/25 Free

Chief Executive Officer

27,344 0.3427%
2/14/25 Other

Chief Technology Officer

768,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
-1.47%+1.57%-86.14%-92.47% 5.2M
+4.21%+25.56%+77.96%+104.49% 68.12B
+0.50%+6.20%+34.94%+67.83% 55.18B
+2.78%+36.87%+23.00%+493.09% 28.63B
+1.78%+18.87%+57.08%+5.18% 23.99B
-0.93%+0.60%-16.89%-12.00% 23.53B
-0.35%+7.91%+44.14%-22.61% 18.45B
+1.42%+10.84%+31.14%+628.97% 16.44B
+7.26%+14.16%+221.03%+393.89% 15.83B
-2.05%-3.81%+40.40%+150.40% 13.4B
Average +0.85%+8.70%+42.67%+171.68% 26.36B
Weighted average by Cap. +1.64%+11.47%+54.01%+163.11%

Financials

2026 *2027 *
Net sales 1.4M 1.22M 1.14M 1.04M 1.96M 134M 1.99M 13.33M 5.23M 67.04M 5.28M 5.16M 223M 2.31M 2M 1.87M 1.71M 3.22M 221M 3.27M 21.94M 8.61M 110M 8.68M 8.49M 367M
Net income -13.52M -11.71M -10.94M -10M -18.85M -1.29B -19.14M -128M -50.35M -645M -50.78M -49.67M -2.15B -15.56M -13.47M -12.59M -11.51M -21.68M -1.48B -22.02M -148M -57.93M -742M -58.42M -57.15M -2.47B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
26-08-10 $0.2010 -1.47% 269,285
26-08-07 $0.2040 -2.11% 320,036
26-08-06 $0.2084 -0.76% 160,945
26-08-05 $0.2100 0.00% 216,770
26-08-04 $0.2100 +6.11% 235,317
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.2010USD
Average target price
8.000USD
Spread / Average Target
+3,880.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock